As you know, on September 16, 2010, FDA held a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (Advisory Committee) to discuss the safety and efficacy of lorcaserin, a drug developed by Arena Pharmaceuticals, Inc. (Arena) to treat obesity.

FORBES: FDA Responds To Outraged Arena Investors

In preparing for the July 2010 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, the FDA sought to provide the committee members with all available data relevant to the cardiovascular safety of rosiglitazone.

FORBES: The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meeting